In line with current international guidelines (e.g., EASL, AASLD), PEG-IFN-α or NAs are recommended as monotherapy for most patients with chronic hepatitis B, rather than as first-line combination therapy, based on considerations of efficacy, safety, and cost-effectiveness. Here, IFNA1 is linked to chronic hepatitis B virus infection.